Table 4. Clinical outcomes of patients who received ROS1 TKI versus those who received chemotherapy.

Cohort (n = 58)	Median follow up (95% CI) in months	Median PFS (95% CI) in months	3 years PFS/5 years PFS	Median OS(95% CI ) in months	3 years OS/5 years OS
ROS1 TKI in 1L (n = 38)	27.4 (95% CI 13.0–50.8)	27.07 (95% CI 24.28–NA)	41.8%/23.9%	48.59 (95% CI 37.85–NA)	71.8%/46.6%
Chemotherapy (n = 20)	14.5 (95% CI 12.1–NA)	6.87 (95% CI 5.55–14.5)	10.53%/5.26%	10.9 (95% CI 7.16–NA)	36.7%/36.7%